


# Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry

Jorge Labrador <sup>1,\*</sup>, David Martínez-Cuadrón <sup>2</sup>, Adolfo de la Fuente <sup>3</sup>, Rebeca Rodríguez-Veiga <sup>2</sup>, Josefina Serrano <sup>4</sup>, Mar Tormo <sup>5</sup>, Eduardo Rodríguez-Arboli <sup>6</sup>, Fernando Ramos <sup>7</sup>, Teresa Bernal <sup>8</sup>, María López-Pavía <sup>9</sup>, Fernanda Trigo <sup>10</sup>, María Pilar Martínez-Sánchez <sup>11</sup>, Juan-Ignacio Rodríguez-Gutiérrez <sup>12</sup>, Carlos Rodríguez-Medina <sup>13</sup>, Cristina Gil <sup>14</sup>, Daniel García Belmonte <sup>15</sup>, Susana Vives <sup>16</sup>, María-Ángeles Foncillas <sup>17</sup>, Manuel Pérez-Encinas <sup>18</sup>, Andrés Novo <sup>19</sup>, Isabel Recio <sup>20</sup>, Gabriela Rodríguez-Macías <sup>21</sup>, Juan Miguel Bergua <sup>22</sup>, Víctor Noriega <sup>23</sup>, Esperanza Lavilla <sup>24</sup>, Alicia Roldán-Pérez <sup>25</sup>, Miguel A. Sanz <sup>2</sup>, Pau Montesinos <sup>2,\*</sup> and (on behalf of PETHEMA group) <sup>†</sup>


Supplementary Figure S1. Univariate analyses of factors influencing response to azacitidine and decitabine.



AML, Acute myeloid leukemia; AZA, azacitidine; CR, complete remission; CRi, complete remission with incomplete blood count recovery; DEC, decitabine; ECOG, Eastern Cooperative Oncology Group; eGFR, estimated glomerular filtration rate;


FLT3, FMS-like tyrosine kinase 3; ITD: internal tandem duplication; NPM1, Nucleophosmin1; ORR, Overall response rate (CR + CRi + PR); PR, partial remission; WBC, White blood cells.

Supplementary Figure S2. Univariate analyses of factors influencing 120-day mortality after azacitidine and decitabine.



AML, Acute myeloid leukemia; AZA, azacitidine; CR, complete remission; CRi, complete remission with incomplete blood count recovery; DEC, decitabine; ECOG, Eastern Cooperative Oncology Group; eGFR, estimated glomerular filtrate rate; FLT3, FMS-like tyrosine kinase 3; ITD: internal tandem duplication; NPM1, Nucleophosmin1; ORR, Overall response rate (CR + CRi + PR); PR, partial remission; WBC, White blood cells.

Supplementary Figure S3. Event free survival and Relapse free survival for azacitidine vs. decitabine.



**Figure 3.** (a) Event free survival for azacitidine vs. decitabine; (b) Event free survival and Relapse free survival for azacitidine vs. decitabine. AZA, azacitidine; DEC, decitabine.

Group Name: Programa Español para el Tratamiento de las Hemopatías Malignas (PETHEMA)